MedTrace Logo

Expanding Phase III Study of Tyroserleutide for Injection

NCT03516448 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2018-05-04

No results posted yet for this study

Summary

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups：6mg/d Tyroserleutide (injection), or placebo

Conditions

Interventions

DRUG

Gan Fu Le Tablets

6 Tablets，tid,po

DRUG

Tyroserleutide for injection

6mg/d, 5days,ivgtt

DRUG

Placebo

0mg/d, 5days,ivgtt

Sponsors & Collaborators

  • Shenzhen Kangzhe Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-24
Primary Completion
2016-06-13
Completion
2019-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516448 on ClinicalTrials.gov